(Q46175272)

7 June 2018

title

Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models (English)

1 reference

7 June 2018

author name string

Daniel Thomas

series ordinal

1

1 reference

7 June 2018

Ravindra Majeti

series ordinal

2

1 reference

7 June 2018

publication date

1 May 2017

1 reference

7 June 2018

published in

Cancer Discovery

1 reference

7 June 2018

volume

7

1 reference

7 June 2018

issue

5

1 reference

7 June 2018

page(s)

459-461

1 reference

7 June 2018

Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5456121

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5456121

Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5456121

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5456121

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5456121

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5456121

Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5456121

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5456121

10.1158/2159-8290.CD-17-0270

15 August 2018

Identifiers

DOI

1 reference

7 June 2018

PMC publication ID

5456121

1 reference

7 June 2018

PubMed publication ID

28461409

1 reference

7 June 2018